Fig. 4: A single dose of THOR-707 drives sustained pSTAT5 signaling, extravasation and proliferation of CD8+ T and NK cells without significant Treg expansion in naive mice. | Nature Communications

Fig. 4: A single dose of THOR-707 drives sustained pSTAT5 signaling, extravasation and proliferation of CD8+ T and NK cells without significant Treg expansion in naive mice.

From: An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism

Fig. 4: A single dose of THOR-707 drives sustained pSTAT5 signaling, extravasation and proliferation of CD8+ T and NK cells without significant Treg expansion in naive mice.

A single intravenous bolus dose of 0.3 mg/kg rhIL-2 or THOR-707 was administrated to naive mice and blood was drawn via cardiac puncture at the indicated time points. Immune cell identification and signaling were assessed by flow cytometry, each data point represents an average of 3–4 replicates at each time point ± standard deviation (SD). a Percentage peripheral blood CD8+ T cells that are pSTAT5 positive. b Percentage of peripheral CD3+ cells that are CD8 positive. c Percentage of singlets (peripheral blood cells sampled) that are NK cells. d Percentage of CD3+ cells that are CD4+ Treg cells (n = 4 animals). Source data are provided as a Source Data file.

Back to article page